Últimas subidas - Macular Degeneration - Age Related, Myopic, Choroidal Neovascular Membranes
|
Myopic CNVM Left Eyevista 82 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 90 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 91 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 89 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 87 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 96 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Myopic CNVM Left Eyevista 106 veces80 year old female. VA dropped to 20/125 but improved back up to 20/50 with VabysmoNoviembre 06, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 84 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 82 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 78 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 73 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 71 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 86 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 86 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 82 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 94 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 67 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 78 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 92 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 92 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 74 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 82 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 84 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 71 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 90 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 80 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 82 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 69 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 93 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 71 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
Wet AMD - Type 1 CNVM - RAP lesionvista 83 veces92 year old man with vision loss and very high PED. Because of worry about a PED tear, patient was treated with avastin, then lucentis, then eyelea, then vabysmo (progressively stronger meds)Septiembre 16, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 139 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 90 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 81 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 73 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 64 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 79 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 70 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 68 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 96 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 73 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 87 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 87 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 80 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 98 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 110 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 83 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 71 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 68 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 79 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 75 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 83 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 93 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 92 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 90 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 103 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 91 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 82 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
wet AMD with classic extrafoveal macular neovascularization in the good eyevista 94 veces89 year old man with longstanding vision loss in the left eye presented with one month of mild vision loss in the right eye. Vision was 20/32. This eye responded to vabysmo therapy.Abril 21, 2024
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 189 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 195 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 175 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 168 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 194 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 180 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 179 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 158 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvista 186 veces69 year old healthy woman with 20/20 vision and no visual complaintsSeptiembre 22, 2023
|
|
Non exudative MNVvista 145 vecesSeptiembre 18, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 180 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 179 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 162 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 148 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 148 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 180 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 182 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 175 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvista 196 veces80 year old female with 20/50 vision in both eyes. Mild blurringSeptiembre 17, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 168 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 169 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 155 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 151 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 166 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 169 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 163 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 159 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 153 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 140 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 163 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 158 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 167 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 152 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 141 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 127 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 178 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 171 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 141 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 160 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 173 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
Myopic (maybe PIC) choroidal neovascular membrane with recurrence after 6 yearsvista 180 veces31 year old female presented with 20/100 vision OS in 2017. Was treated with Lucentis x 6 and improved to 20/32. Then she was lost to follow-up. She represented 6 years later with 20/50 vision OS and a large recurrence and restarted treatment.Septiembre 16, 2023
|
|
| 2694 archivos en 27 página(s) |
 |
3 | |
|
|
|
|
|
|
|
|
